Based on the AURA trial for EGFR driver‐positive NSCLC patients, the third‐generation EGFR tyrosine kinase inhibitor (TKI) osimertinib has become the standard of care for patients with T790M mutations who acquired resistance to first‐ and second‐generation EGFR‐TKIs.3 Here, EGFR is linked to non-small cell lung carcinoma.